Zacks Investment Research Upgrades Isotechnika Pharma (AUPH) to Hold

Zacks Investment Research upgraded shares of Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) from a sell rating to a hold rating in a research report report published on Thursday.

According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “

How to Become a New Pot Stock Millionaire

A number of other research analysts also recently issued reports on the stock. Cantor Fitzgerald set a $16.00 target price on shares of Isotechnika Pharma and gave the company an overweight rating in a research report on Thursday, March 15th. ValuEngine upgraded shares of Isotechnika Pharma from a sell rating to a hold rating in a research report on Sunday, December 31st. BidaskClub upgraded shares of Isotechnika Pharma from a strong sell rating to a sell rating in a research report on Friday, January 5th. Royal Bank of Canada started coverage on shares of Isotechnika Pharma in a research report on Thursday, February 8th. They set an outperform rating and a $9.00 target price for the company. Finally, Seaport Global Securities restated a buy rating and set a $11.00 target price on shares of Isotechnika Pharma in a research report on Friday, March 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Isotechnika Pharma currently has an average rating of Buy and an average target price of $10.93.

NASDAQ AUPH traded down $0.10 on Thursday, reaching $5.10. 291,260 shares of the company’s stock traded hands, compared to its average volume of 791,949. The company has a market capitalization of $444.63, a PE ratio of -5.57 and a beta of 2.26. Isotechnika Pharma has a fifty-two week low of $4.41 and a fifty-two week high of $8.19.

Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, March 15th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. Isotechnika Pharma had a negative net margin of 16,855.24% and a negative return on equity of 17.54%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.11) earnings per share. equities analysts predict that Isotechnika Pharma will post -0.7 earnings per share for the current year.

Institutional investors have recently modified their holdings of the business. Spark Investment Management LLC acquired a new position in shares of Isotechnika Pharma in the fourth quarter worth about $153,000. Wells Fargo & Company MN raised its position in shares of Isotechnika Pharma by 13,197.5% in the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 26,395 shares during the period. Cutler Capital Management LLC raised its position in shares of Isotechnika Pharma by 25.0% in the fourth quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 10,000 shares during the period. Swiss National Bank acquired a new position in shares of Isotechnika Pharma in the fourth quarter worth about $421,000. Finally, Kazazian Asset Management LLC raised its position in shares of Isotechnika Pharma by 11.6% in the fourth quarter. Kazazian Asset Management LLC now owns 156,126 shares of the biotechnology company’s stock worth $707,000 after acquiring an additional 16,189 shares during the period. Institutional investors and hedge funds own 28.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3335825/zacks-investment-research-upgrades-isotechnika-pharma-auph-to-hold.html.

About Isotechnika Pharma

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.

Get a free copy of the Zacks research report on Isotechnika Pharma (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Isotechnika Pharma (NASDAQ:AUPH)

Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

21Vianet Group  Receives Daily Media Impact Rating of 0.16
21Vianet Group Receives Daily Media Impact Rating of 0.16
Frontier Communications  Receives Coverage Optimism Score of 0.24
Frontier Communications Receives Coverage Optimism Score of 0.24
QAD  Receives News Sentiment Rating of 0.05
QAD Receives News Sentiment Rating of 0.05
Head-To-Head Contrast: Magellan Health  & Mednax
Head-To-Head Contrast: Magellan Health & Mednax
WA Space Trading Up 18.2% Over Last 7 Days
WA Space Trading Up 18.2% Over Last 7 Days
Sentinel Market Cap Reaches $0.00
Sentinel Market Cap Reaches $0.00


© 2006-2018 Ticker Report. Google+.